

Data Sheet

Product Name:	Leronlimab
Cat. No.:	CS-0628950
CAS No.:	674782-26-4
Target:	CCR; HIV
Pathway:	Anti-infection; GPCR/G Protein; Immunology/Inflammation
Solubility:	10 mM in DMSO

Leronlimab

BIOLOGICAL ACTIVITY:

Leronlimab (PRO 140) is a humanized IgG4 **anti-CCR5** monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer^[1]. *In Vitro*:Leronlimab (1-140 mg/mL) binds to CCR5-positive cells up to 98%^[1].

Leronlimab (80-1750 µg/mL) blocks CCL5, CCL3, and CCL4-induced calcium responses in MDA-MB-231-CCR5 cells^[1].

Leronlimab (175 and 350 mg/mL) blocks MDA-MB-231 cell invasion^[1].

Leronlimab (10 µg/mL; 72 hours) enhances the cytotoxicity of doxorubicin for MDA-MB-231 cells^[1]. *In Vivo*:Leronlimab (2 mg; i.p., twice a week) reduces lung metastasis in murine xenograft models^[1].

References:

[1]. Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. *Breast Cancer Res.* 2021 Jan 23;23(1):11.

CAIndexNames:

Immunoglobulin G4, anti-(human Chemokine receptor CCR5) (humanized monoclonal PRO 140 γ 4-chain), disulfide with humanized monoclonal PRO 140 κ -chain, dimer

SMILES:

[Leronlimab]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA